Mizuho Maintains Buy on Axsome Therapeutics, Raises Price Target to $112
Portfolio Pulse from Benzinga Newsdesk
Mizuho analyst Graig Suvannavejh maintains a Buy rating on Axsome Therapeutics (AXSM) and raises the price target from $90 to $112.

February 16, 2024 | 11:48 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Mizuho analyst Graig Suvannavejh reaffirmed a Buy rating on Axsome Therapeutics and increased the price target from $90 to $112.
The increase in price target by a reputable analyst like Graig Suvannavejh signals a strong confidence in Axsome Therapeutics' future performance. This endorsement is likely to positively influence investor sentiment and potentially drive up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100